SCHEMBL5453060

SCHEMBL5453060

NC(=O)c1c(NC(=O)Nc2ccc(F)c(Cl)c2)sc2c1CCOC2

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CFTR P13569 1/20 0.54
KCNH2 Q12809 8/20 0.54
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
KDM4E B2RXH2 1/20 0.54
USP2 O75604 1/20 0.54
LMNA P02545 1/20 0.54
MAPT P10636 1/20 0.54
HTT P42858 1/20 0.54
ATM Q13315 1/20 0.54
ANO1 Q5XXA6 3/20 0.49
SLC2A1 P11166 1/20 0.47
ALDH1A1 P00352 1/20 0.47
CNR2 P34972 2/20 0.46
CNR1 P21554 1/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
EPHB4 P54760 1/20 0.46
CXCR2 P25025 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5454317 0.92 MEN1 (0.63) CFTRKCNH2MEN1KMT2AKDM4E
SCHEMBL5450806 0.91 CFTR (0.57) CFTRKCNH2MEN1KMT2AKDM4E
SCHEMBL16962264 0.87 KCNH2 (0.68) CFTRKCNH2MEN1KMT2AKDM4E
SCHEMBL5461010 0.87 CFTR (0.58) CFTRKCNH2MEN1KMT2AKDM4E
SCHEMBL5460167 0.87 KDR (0.60) CFTRKCNH2MEN1KMT2AKDM4E
SCHEMBL5457888 0.86 ANO1 (0.64) CFTRKCNH2MEN1KMT2AKDM4E
SCHEMBL5467205 0.86 CFTR (0.56) CFTRKCNH2MEN1KMT2AKDM4E
SCHEMBL5446288 0.85 MAPT (0.59) CFTRKCNH2MEN1KMT2AKDM4E
SCHEMBL5457877 0.85 CFTR (0.57) CFTRKCNH2MEN1KMT2AKDM4E
SCHEMBL5454365 0.85 CFTR (0.55) CFTRKCNH2MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 CFTR 2030/4885KCNH2 3409/4885MEN1 2891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.